Medicxi unveils €500m fund for asset-centric biotechs

London-headquartered investment firm Medicxi has unveiled a €500m ($580m) fund to back innovative biotechs, set against a backdrop of growing concern at the state of the commercial landscape in Europe compared to the US. Medicxi, a self-ascribed European life sciences venture capital firm, has dubbed the fund Medicxi V, which will focus on an asset-centric investment model. Medicxi will use the €500m kitty to continue supporting drug hunters and entrepreneurs in creating asset-focused biotechnology compa ...